Xeljanz · DIN 02480786 · 10 mg · tablet
Limited Use, Reason for Use code 589 requiredMarketed · checked November 17, 2026
StatusLimited Use, Reason for Use code 589 required
Write on scriptReason for Use code 589 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 589
Reason for Use code 589
For the treatment of ulcerative colitis disease in patients who meet the following criteria:
1. Moderate disease
a. Mayo score between 6 and 10 (inclusive) AND
b. Endoscopic* subscore of 2 AND
c. Failed 2 weeks of oral prednisone at daily doses greater than or equal to 40mg (or a 1 week course of IV equivalent)
OR
d. Stabilized with 2 weeks oral prednisone at daily doses greater than or equal to 40mg (or 1 week of IV equivalent) but demonstrated that the corticosteroid dose cannot be tapered despite 3 months of AZA/6MP (or where the use of immunosuppressants is contraindicated).
2. Severe disease
a. Mayo score greater than 10 AND
b. Endoscopy* subscore of greater than or equal to 2 AND
c. Failed 2 weeks of oral prednisone at daily doses greater than or equal to 40mg (or 1 week of IV equivalent)
OR
d. Stabilized with 2 weeks oral prednisone at daily doses greater than or equal to 40mg (or 1 week of IV equivalent) but demonstrated that the corticosteroid dose cannot be tapered despite 3 months of AZA/6MP (or where the use of immunosuppressants is contraindicated).
*The endoscopy procedure must be done within the 12 months prior to initiation of treatment.
The recommended dosing regimen for induction is 10mg twice daily for at least 8 weeks.
Maintenance/Renewal:
Maintenance therapy is funded for patients who meet the Ministry initiation criteria and whose disease is maintained at Mayo score less than 6 AND who demonstrate at least 50% reduction in the dose of prednisone compared with the starting dose following the first 6 months of treatment with tofacitinib or be off corticosteroids after the first year of treatment.
The recommended dosing regimen is 5mg twice daily.
Depending on therapeutic response; 10mg twice daily may also be used for maintenance in some patients. However, the lowest effective dose possible should be used for maintenance therapy to minimize adverse effects.
Coverage limit:
LU Authorization Period: 1 year
Savings card: RxHelp ONE lists XELJANZ (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Xeljanz · DIN 02480786
Manufacturer: Pfizer Canada Inc.; listing date 2020-09-30
Health Canada: Marketed since 2019-01-30 · brand XELJANZ · ATC L04AF01 TOFACITINIB · form Tablet · route Oral · ingredients TOFACITINIB (TOFACITINIB CITRATE) 10 MG · company Pfizer canada ulc · schedule Prescription
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02480786)
Source record
DIN 02480786: Xeljanz
Raw flags: sec12=Y, sec3=Y
Item: 923600016; group id 1044; item number 2399; lccId 00341; manufacturer id PFI
Source form: Tab; strength: 10mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $43.7833; ministry $10.5859
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02480786
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97137
Interchangeable products
Auro-Tofacitinib · DIN 02530015 · $10.5859
Sandoz Tofacitinib · DIN 02551705 · $10.5859
Taro-Tofacitinib · DIN 02511312 · $10.5859
Shortage status: not checked (no credentials)